Citius Oncology (CTOR) Retained Earnings (2022 - 2026)
Citius Oncology (CTOR) posted quarterly Retained Earnings of -$96.2 million for Q1 2026, down 79.2% year-over-year from -$462.5 million in Q1 2025, and down 38.25% quarter-over-quarter from -$69.6 million in Q4 2025.
Citius Oncology (CTOR) Retained Earnings (2022 - 2026) Analysis & Trends
Citius Oncology (CTOR) has reported Retained Earnings for 5 consecutive years, with -$96.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings fell 79.2% year-over-year to -$96.2 million; the TTM figure through Mar 2026 stood at -$96.2 million (down 79.2% YoY), while the FY2025 annual figure was -$64.0 million, down 174.98% from the prior year.
- Retained Earnings eased to -$96.2 million in Q1 2026 per CTOR's latest filing, from -$69.6 million in the prior quarter.
- Across five years, Retained Earnings topped out at $85.4 million in Q3 2024 and bottomed at -$96.2 million in Q1 2026.
- Historically, Retained Earnings has averaged -$19.0 million across 5 years, with a median of -$2.7 million in 2024.
- On a YoY basis, Retained Earnings climbed as much as 95.63% in 2024 and fell as far as 137461.86% in 2024.
- Citius Oncology's Retained Earnings stood at $345266.0 in 2022, then plunged by 675.71% to -$2.0 million in 2023, then tumbled by 2211.07% to -$45.9 million in 2024, then sank by 51.45% to -$69.6 million in 2025, then plunged by 38.25% to -$96.2 million in 2026.
- Business Quant data shows CTOR's Retained Earnings at -$96.2 million in Q1 2026, -$69.6 million in Q4 2025, and -$64.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.15 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 28.26 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 14.65 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 4.18 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 9.16 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.56 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 724.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 8.88 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.75 Bn |
| 10 | Citius Oncology | 80.25 Mn | 80.25 Mn | 1.00 Mn | 145.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.18 Mn |
| Dec 31, 2025 | -69.57 Mn |
| Sep 30, 2025 | -64.04 Mn |
| Jun 30, 2025 | -59.04 Mn |
| Mar 31, 2025 | -53.67 Mn |
| Dec 31, 2024 | -45.94 Mn |
| Sep 30, 2024 | 85.41 Mn |
| Jun 30, 2024 | -3.04 Mn |
| Mar 31, 2024 | -2.46 Mn |
| Dec 31, 2023 | -1.99 Mn |
| Sep 30, 2023 | 43.66 Mn |
| Jun 30, 2023 | -2,210.00 |
| Mar 31, 2023 | 197,344.00 |
| Dec 31, 2022 | 345,266.00 |